Antihypertensive treatment with beta-blockers in the metabolic syndrome: A review

Current Diabetes Reviews

Volumn 6, Issue 4, 2010, Pages 215-221

  Carella, Angelo M ^a   Antonucci, Giuseppe ^a   Conte, Matteo ^a   Di Pumpo, Michele ^a   Giancola, Armando ^a   Antonucci, Elisabetta ^a  

^a T Masselli Mascia Hospital   (Italy)

Author keywords

Antihypertensive; Beta blockers; Metabolic syndrome

Indexed keywords

AMOSULALOL; ANGIOTENSIN RECEPTOR ANTAGONIST; AROTINOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVANTOLOL; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LABETALOL; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; PINDOLOL; PROPRANOLOL; SOTALOL;

ADRENERGIC RECEPTOR BLOCKING; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG UTILIZATION; ENERGY EXPENDITURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; VASODILATATION; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; CARBAZOLES; ETHANOLAMINES; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; PROPANOLAMINES; VASODILATOR AGENTS;

EID: 77954685772     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339910791658844     Document Type: Article

References (110)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-607.
2. Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-78.
3. Lorenzo C, Okoloise M, Williams K, et al. San Antonio heart study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26: 3153-9.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2846-97.
5. Balkau B, Charles MA, Drivsholm T, et al. European group for the study of insulin resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28(5): 364-76.
6. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(3): 237-52.
7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-52.
8. Athyros VG, Ganotakis ES, Elisaf M, et al. The IDF Consensus Worldwide Definition of the Metabolic Syndrome [article online], 2005. Available at http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf [accessed June 7, 2005].
9. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted sindrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3): 173-94.
10. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104(6): 787-94.
11. Lastra G, Manrique CM, Hayden MR. The role of beta-cell disfunction in the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1(1): 41-6.
12. Paolisso G, Howard BV. Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet Med 1998; 15(5): 359.
13. Maedler K, Spinas GA, Lehmann R, et al. Glucose induces betacells apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001; 50(8): 1683-90.
14. Giles TD, Sander GE. Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome. J Clin Hypertens 2005; 7(11): 669-78.
15. Wagh A, Stone NJ. Treatment of metabolic syndrome. Expert Rev Cardiovasc Ther 2004; 2(2): 213-28.
16. Black HR. Metabolic considerations in the choice of therapy for the patient with Hypertension. Am Heart J 1991; 121: 707-15.
17. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-52.
18. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
19. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203-9.
20. Lind L, Pollare T, Berne C, et al. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128(6 Pt 1): 1177-83.
21. Lithell HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens 1996; 9(11): 150S-154S.
22. Sarafidis PA, Bakris GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens 2007; 25(1): 249-52.
23. Nadelmann J, Frishman WH. Clinical use of beta-adrenoceptor blockade in systemic hypertension. Drugs 1990; 39(6): 862-76.
24. Thadani U. Beta blockers in hypertension. Am J Cardiol 1983; 52(9): 10D-15D.
25. van den Meiracker AH, Man in't Veld AJ, van Eck HJ, et al. Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation 1988; 78(4): 957-68.
26. Manin't Veld AJ, Schalekamp MADH. Effects on 10 different - adrenoceptor antagonists on hemodynamics, plasma renin activity, and norepinephrine in hypertension: the key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmacol 1983; 5: S30-S45.
27. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J 1987; 113(5): 1190-8.
28. McDevitt DG. Comparison of pharmacokinetic properties of beta- adrenoceptor blocking drugs. Eur Heart J 1987; 8(Suppl M): 9-14.
29. Kendall MJ. Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol 1997; 80(9B): 15J-19J.
30. Prichard BN. Combined alpha- and beta-receptor inhibition in the treatment of hypertension. Drugs 1984; 28(Suppl 2): 51-68.
31. Prichard BN. Pharmacologic aspects of intrinsic sympathomimetic activity in beta-blocking drugs. Am J Cardiol 1987; 59: 13F-17F.
32. Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet 1985; 1: 123-6.
33. Rabkin SW. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993; 33(3): 286-91.
34. Wolinsky H. The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987; 10(10): 561-6.
35. Day JL, Metcalfe J, Simpson N, et al. Adrenergic mechanisms in the control of plasma lipids in man. Am J Med 1984; 76(2A): 94-6.
36. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-72.
37. Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300: 902-3.
38. Davis BR, Oberman A, Blaufox MD, et al. Effect of antihypertensive therapy on weight loss: the Trial of Antihypertensive Interventions and Management Research Group. Hypertension 1992; 19: 393-99.
39. Bjorck S, Mulec H, Johnsen SA, et al. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ 1990; 300: 904-7.
40. Zanchetti A, Hennig M, Baurecht H, et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intimamedia thickness. J Hypertens 2007; 25(12): 2463-70.
41. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a north of sweden efficacy evaluation (ALPINE study). J Hypertens 2003; 21(8): 1563-74.
42. Uzunlulu M, Oguz A, Yorulmaz E. The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. Int Heart J 2006; 47(3): 421-30.
43. Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Int J Clin Pract Suppl 2004; (139): 26-32.
44. Fragasso G, Cattaneo N, Locatelli M, et al. Differential effects of selective beta-adrenergic blockade on insulin sensitivity and release in control subjects and in patients with angina and normal coronary arteries (syndrome X). G Ital Cardiol 1998; 28(6): 623-9.
45. Piecha G, Adamczak M, Chudek J, et al. Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res 2007; 30(3): 187-94.
46. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12(2): 147-53.
47. Maison P, Byrne CD, Hales CN, et al. Hypertension and its treatment influence changes in fasting nonesterified fatty acid concentrations: a link between the sympathetic nervous system and the metabolic syndrome? Metabolism 2000; 49(1): 81-7.
48. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24(3): 591-6.
49. Siegel D, Swislocki AL. Effects of antihypertensives on glucose metabolism. Metab Syndr Relat Disord 2007; 5(3): 211-9.
50. Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2000; 2(4): 370-7.
51. Deshmukh M, Lee HW, McFarlane SI, et al. Antihypertensive medications and their effects on lipid metabolism. Curr Diab Rep 2008; 8(3): 214-20.
52. Kovaci D, Marinsek M, Gobec L, et al. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008; 97(1): 24-31.
53. Kunz I, Schorr U, Klaus S, et al. Resting metabolic rate and substrate use in obesity hypertension. Hypertension 2000; 36: 26-32.
54. Sharma AM, Pischon T, Hardt S, et al. Hypothesis: Beta- adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37(2): 250-4.
55. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta- blockers and the spectrum of glycaemic control. QJM 2006; 99(7): 431-6.
56. Holzgreve H, Nakov R, Beck K, et al. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003; 16: 381-6.
57. Mykkänen L, Kuusisto J, Pyörälä K, et al. Increased risk of noninsulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertens 1994; 12(12): 1425-32.
58. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100(8): 1254-62.
59. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004; 27: 247-55.
60. Malmberg K, Norhammar A, Wedel H, Rydén L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626-32.
61. Molinoff PB. Alpha- and beta-adrenergic receptor subtypes properties, distribution and regulation. Drugs 1984; 28(Suppl 2): 1-15.
62. Hagström-Toft E, Enoksson S, Moberg E, et al. beta-Adrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo. Am J Physiol 1998; 275(6 Pt 1): E909-16.
63. Schmelck PH, Hanoune J. The hepatic adrenergic receptors. Mol Cell Biochem 1980; 33(1-2): 35-48.
64. Ahrén B. Autonomic regulation of islet hormone secretion-- implications for health and disease. Diabetologia 2000; 43(4): 393-410.
65. Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res 2006; 53(6): 482-91.
66. Schauer UJ, Schauer I. Inhibition of human lecithin: cholesterol acyltransferase activity by catecholamines in vitro. Biomed Biochim Acta 1989; 48(10): 849-52.
67. Large V, Arner P. Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab 1998; 24(5): 409-18.
68. Barth E, Albuszies G, Baumgart K, et al. Glucose metabolism and catecholamines. Crit Care Med 2007; 35(9 Suppl): S508-18.
69. Krone W, Nägele H. Metabolic changes during antihypertensive therapies. J Hum Hypertens 1989; 3(Suppl 2): 69-73.
70. Lipworth BJ. Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol 1996; 42(3): 291-300.
71. Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993; 34(7): 1057-91.
72. Chernogubova E, Cannon B, Bengtsson T. Norepinephrine increases glucose transport in brown adipocytes via beta3- adrenoceptors through a cAMP, PKA, and PI3-kinase-dependent pathway stimulating conventional and novel PKCs. Endocrinology 2004; 145(1): 269-80.
73. de Souza CJ, Burkey BF. Beta 3-adrenoceptor agonists as antidiabetic and anti-obesity drugs in humans. Curr Pharm Des 2001; 7(14): 1433-49.
74. Natali A, Santoro D, Palombo C, et al. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 1991; 17(2): 170-8.
75. Julius S, Gudbrandsson T, Jamerson K, et al. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. Blood Press 1992; 1(1): 9-19.
76. Julius S, Gudbrandsson T, Jamerson K, et al. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9(11): 983-6.
77. Leren P, Eide I, Foss OP, et al. Antihypertensive drugs and blood lipids: the Oslo study. Br J Clin Pharmacol 1982; 13(Suppl 2): 441S-444S.
78. Aellig WH. Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. Br J Clin Pharmacol 1982; 13(Suppl 2): 187S-192S.
79. Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298(6681): 1152-7.
80. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992; 1(2): 92-101.
81. Basat O, Ucak S, Seber S, et al. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol 2006; 95(2): 99-104.
82. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14(4): 489-94.
83. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126(12): 955-9.
84. Poirier L, Cléroux J, Nadeau A, et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19(8): 1429-35.
85. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11(11): 753-7
86. Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8(2): 127-34.
87. Bakris GL, Fonseca V, Katholi RE, et al.; GEMINI Investigators. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292(18): 2227-36.
88. Schmidt AC, Graf C, Brixius K, et al. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig 2007; 27(12): 841-9.
89. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta- adrenoceptor antagonist with unique characteristics. Drugs 2007; 67(8): 1097-107.
90. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16(Suppl F): 38-42.
91. Jacob S, Balletshofer B, Henriksen EJ, et al. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta- blockers. Blood Press 1999; 8(5-6): 261-8.
92. Ogihara T, Asano T, Katagiri H, et al. Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 2004; 47(5): 794-805.
93. Kajimoto Y, Kaneto H. Role of oxidative stress in pancreatic beta- cell dysfunction. Ann N Y Acad Sci 2004; 1011: 168-76.
94. Kaneto H, Kawamori D, Matsuoka TA, et al. Oxidative stress and pancreatic beta-cell dysfunction. Am J Ther 2005; 12(6): 529-33.
95. Frishman WH. Carvedilol. N Engl J Med 1998; 339(24): 1759-65.
96. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and -adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-8.
97. Franconi F, Tadolini B. Carvedilol inhibition of lipid peroxidation. A new antioxidative mechanism. Free Radic Res 1998; 29: 377-87.
98. Yoshioka T, Iwamoto N, Tsukahara F, Irie K, Urakawa I, Muraki T. Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells. Br J Pharmacol 2000; 129(7): 1530-5.
99. Butler S, Wang R, Wunder SL, Cheng HY, Randall CS. Perturbing effects of carvedilol on a model membrane system: role of lipophilicity and chemical structure. Biophys Chem 2006; 119(3): 307-15.
100. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000; 36(2): 277-81.
101. Lund-Johansen P. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. Drugs 1984; 28(Suppl 2): 35-50.
102. Louis WJ, McNeil JJ, Drummer OH. Pharmacology of combined alpha-beta-blockade. I. Drugs 1984; 28(Suppl 2): 16-34.
103. van Zwieten PA. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Dugs 1993; 45: 509-17.
104. Kageyama S, Yamamoto J, Mimura A, Sakurai T, Ishibashi K, Isogai Y. Effect of arotinolol on insulin sensitivity in obese hypertensive patients. Clin Ther 1994; 16: 981-8.
105. Vaughan Williams EM. Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol 1987; 27(7): 450-60.
106. Cockcroft J. Nebivolol: a review. Expert Opin Pharmacother 2004; 5(4): 893-9.
107. Gupta S, Wright HM. Nebivolol: a highly selective beta- 1adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008; 26(3): 189-202.
108. Gosgnach W, Boixel C, Nèvo N, et al. Nebivolol induces calcium- independent signalling in endothelial cells by a possible beta- adrenergic pathway. J Cardiovasc Pharmacol 2001; 38(2): 191-9.
109. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3- adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta- blocker nebivolol. Circulation 2005; 112(8): 1198-205.
110. Celik T, Yuksel UC, Iyisoy A, et al. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with me- toprolol. Int J Cardiol 2007; 116: 206-11.